Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial

Valérie Fonteyne, Guy Soete, Stefano Arcangeli, Wilfried De Neve, Bernard Rappe, Guy Storme, Lidia Strigari, Giorgio Arcangeli, Gert De Meerleer

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report late gastrointestinal (GI) and genitourinary (GU) toxicity, biochemical and clinical outcomes, and overall survival after hypofractionated radiation therapy for prostate cancer (PC). Methods and Materials: Three institutions included 113 patients with T1 to T3N0M0 PC in aphase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Late toxicity was scored using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms. Biochemical outcome was reported according to the Phoenix definition for biochemical failure. Results: The incidence of late GI and GU toxicity was low. The 3-year actuarial risk of developing late GU and GI toxicity of grade ≥2 was 13% and 8% respectively. Five-year biochemical non-evidence of disease (bNED) was 94%. Risk group, T stage, and deviation from planned hormone treatment were significant predictive factors for bNED. Deviation from hormone treatment remained significant in multivariate analysis. Five-year clinical non evidence of disease and overall survival was 95% and 91% respectively. No patient died from PC. Conclusions: Hypofractionated high-dose radiation therapy is a valuable treatment option for patients with PC, with excellent biochemical and clinical outcome and low toxicity.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number4
DOIs
Publication statusPublished - Nov 15 2012

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint

Dive into the research topics of 'Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial'. Together they form a unique fingerprint.

Cite this